JP2005507647A5 - - Google Patents

Download PDF

Info

Publication number
JP2005507647A5
JP2005507647A5 JP2003514001A JP2003514001A JP2005507647A5 JP 2005507647 A5 JP2005507647 A5 JP 2005507647A5 JP 2003514001 A JP2003514001 A JP 2003514001A JP 2003514001 A JP2003514001 A JP 2003514001A JP 2005507647 A5 JP2005507647 A5 JP 2005507647A5
Authority
JP
Japan
Prior art keywords
ser
peptide
leu
pharmaceutical composition
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003514001A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005507647A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2002/001105 external-priority patent/WO2003008443A2/en
Publication of JP2005507647A publication Critical patent/JP2005507647A/ja
Publication of JP2005507647A5 publication Critical patent/JP2005507647A5/ja
Pending legal-status Critical Current

Links

JP2003514001A 2001-07-19 2002-07-19 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド Pending JP2005507647A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30616101P 2001-07-19 2001-07-19
US30615001P 2001-07-19 2001-07-19
US33147701P 2001-11-16 2001-11-16
PCT/CA2002/001105 WO2003008443A2 (en) 2001-07-19 2002-07-19 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011035954A Division JP2011152133A (ja) 2001-07-19 2011-02-22 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド

Publications (2)

Publication Number Publication Date
JP2005507647A JP2005507647A (ja) 2005-03-24
JP2005507647A5 true JP2005507647A5 (cg-RX-API-DMAC7.html) 2006-01-05

Family

ID=27405149

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2003514001A Pending JP2005507647A (ja) 2001-07-19 2002-07-19 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド
JP2003514002A Expired - Lifetime JP4587667B2 (ja) 2001-07-19 2002-07-19 細胞の除去又は破壊を必要とする腫瘍及び他の状態の治療に有効なペプチド
JP2011035954A Pending JP2011152133A (ja) 2001-07-19 2011-02-22 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド
JP2013078281A Expired - Lifetime JP5622885B2 (ja) 2001-07-19 2013-04-04 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2003514002A Expired - Lifetime JP4587667B2 (ja) 2001-07-19 2002-07-19 細胞の除去又は破壊を必要とする腫瘍及び他の状態の治療に有効なペプチド
JP2011035954A Pending JP2011152133A (ja) 2001-07-19 2011-02-22 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド
JP2013078281A Expired - Lifetime JP5622885B2 (ja) 2001-07-19 2013-04-04 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド

Country Status (22)

Country Link
US (2) US7192929B2 (cg-RX-API-DMAC7.html)
EP (2) EP1417227B1 (cg-RX-API-DMAC7.html)
JP (4) JP2005507647A (cg-RX-API-DMAC7.html)
KR (2) KR100966232B1 (cg-RX-API-DMAC7.html)
CN (1) CN100475843C (cg-RX-API-DMAC7.html)
AT (1) ATE353914T1 (cg-RX-API-DMAC7.html)
AU (2) AU2002319049B2 (cg-RX-API-DMAC7.html)
BR (2) BR0211199A (cg-RX-API-DMAC7.html)
CA (2) CA2453967C (cg-RX-API-DMAC7.html)
CY (1) CY1108009T1 (cg-RX-API-DMAC7.html)
DE (2) DE60217507T2 (cg-RX-API-DMAC7.html)
DK (1) DK1417228T3 (cg-RX-API-DMAC7.html)
EA (1) EA006603B1 (cg-RX-API-DMAC7.html)
ES (2) ES2281529T3 (cg-RX-API-DMAC7.html)
IL (2) IL159903A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04000561A (cg-RX-API-DMAC7.html)
NO (1) NO333999B1 (cg-RX-API-DMAC7.html)
NZ (2) NZ531114A (cg-RX-API-DMAC7.html)
PL (1) PL207588B1 (cg-RX-API-DMAC7.html)
PT (1) PT1417228E (cg-RX-API-DMAC7.html)
WO (2) WO2003008444A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200401320B (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050245451A1 (en) * 2000-04-05 2005-11-03 Pincus Matthew R Peptides selectively lethal to malignant and transformed mammalian cells
DE60222745T2 (de) * 2001-03-08 2008-07-10 Nymox Pharmaceutical Corp., St. Laurent Verwendung von neurofilamentproteinen zur behandlung von tumoren
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
DE60217507T2 (de) * 2001-07-19 2007-11-15 Nymox Corp., Saint-Laurent Peptide für die behandlung von tumoren und anderen zuständen, die das entfernen oder zerstören von zellen erfordern
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
WO2003048188A2 (en) * 2001-12-04 2003-06-12 Millennium Pharmaceuticals, Inc. 15603, a human ion channel family member
EP1646648A2 (en) * 2003-07-15 2006-04-19 Genova Ltd. Secreted polypeptide species reduced in cardiovascular disorders
CN1822853A (zh) * 2003-07-15 2006-08-23 加拿大国家研究委员会 用于治疗特征在于过度增殖皮肤细胞的疾病的人类甲状旁腺激素环状类似物
CA2555306A1 (en) * 2004-02-06 2005-08-18 Nymox Corporation Humanized antibody
US20060173490A1 (en) 2005-02-01 2006-08-03 Boston Scientific Scimed, Inc. Filter system and method
PL1994152T3 (pl) 2006-02-28 2013-05-31 Nymox Corp Peptydy skuteczne w leczeniu nowotworów i innych stanów wymagających usunięcia lub zniszczenia komórek
EA200801942A1 (ru) * 2006-03-10 2009-02-27 Наймокс Корпорейшн Способ предотвращения или уменьшения риска возникновения рака с использованием пептидов на основе белков нервных волокон
US20080027005A1 (en) * 2006-07-31 2008-01-31 Paul Averback Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
TR201802233T4 (tr) * 2007-10-25 2018-03-21 Toray Industries İmmün cevap indükleyiciler.
JP5572938B2 (ja) * 2007-10-25 2014-08-20 東レ株式会社 免疫誘導剤
EP2224961A1 (en) * 2007-11-26 2010-09-08 The Research Foundation of the State University of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
KR20110015571A (ko) * 2008-04-24 2011-02-16 더리무넥 파마큐티컬스, 아이엔씨. 펩티딜 디아실글리세라이드
ES2874306T3 (es) 2010-09-29 2021-11-04 Agensys Inc Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12
US20160250298A1 (en) 2013-11-01 2016-09-01 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
US20160215031A1 (en) * 2015-01-27 2016-07-28 Nymox Pharnaceutical Corporation Method of treating disorders requiring destruction or removal of cells
US20160361380A1 (en) * 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
US11628202B2 (en) * 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) * 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) * 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
US10835538B2 (en) 2018-03-28 2020-11-17 Nymox Corporation Method of treating benign prostatic hyperlasia with antibiotics
WO2019195851A1 (en) 2018-04-06 2019-10-10 Oncolyze, Inc. Compositions for use in lysis of selective cancer cells
US20200061150A1 (en) 2018-08-23 2020-02-27 Nymox Corporation Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function
EA202191201A1 (ru) 2018-12-03 2022-01-26 Эдженсис, Инк. Фармацевтические композиции, включающие конъюгаты анти-191p4d12 антитело-лекарственное средство, и способы их применения
US11278588B2 (en) 2019-05-13 2022-03-22 Nymox Corporation Method of treating lower urinary tract symptoms with fexapotide triflutate
US20200360466A1 (en) 2019-05-13 2020-11-19 Nymox Corporation Method of improving lower urinary tract symptoms
US11298400B2 (en) 2019-05-13 2022-04-12 Nymox Corporation Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS
US11331374B2 (en) 2019-07-31 2022-05-17 Nymox Corporation Focal treatment of prostate cancer
US11231421B2 (en) 2019-07-31 2022-01-25 Nymox Corporation Methods of treating multifocal cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0378924B1 (en) * 1988-12-21 1996-11-13 The General Hospital Corporation Detection of neurological disease or dysfunction
US5948634A (en) * 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
AU749348B2 (en) * 1997-02-26 2002-06-27 General Hospital Corporation, The Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease
AU765110B2 (en) * 1998-06-26 2003-09-11 Georgetown University Medical Center Compositions and methods for inducing cell death
AU2185199A (en) * 1998-09-30 2000-04-17 Yoko Aida Apoptosis inducers
EP1135494A2 (en) * 1998-12-11 2001-09-26 Incyte Pharmaceuticals, Inc. Neuron-associated proteins
DE60003632T2 (de) * 1999-01-11 2004-04-15 Leadd B.V. Verwendung von apoptose-induzierende mittel zur herstellung eines mittels zur behandlung von (auto)immunkrankheiten
AU3517000A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. 50 human secreted proteins
JP2002543764A (ja) * 1999-03-19 2002-12-24 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 46個のヒト分泌タンパク質
JP2002539842A (ja) 1999-03-26 2002-11-26 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 45個のヒト分泌タンパク質
EP1220947A2 (en) * 1999-03-26 2002-07-10 Human Genome Sciences, Inc. 50 human secreted proteins
EP1171462A2 (en) 1999-03-26 2002-01-16 Human Genome Sciences, Inc. 49 human secreted proteins
CN1300779A (zh) * 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽-人神经元线蛋白17和编码这种多肽的多核苷酸
CN1300783A (zh) 1999-12-23 2001-06-27 上海生元基因开发有限公司 新的人神经元线蛋白及其编码序列
WO2002000718A2 (en) * 2000-06-26 2002-01-03 Millennium Pharmaceuticals, Inc. A human calcium channel protein and uses thereof
CN1352145A (zh) * 2000-11-10 2002-06-05 上海博德基因开发有限公司 一种新的多肽——锌指蛋白14.08和编码这种多肽的多核苷酸
US6783969B1 (en) * 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
BR0209990A (pt) * 2001-05-25 2004-06-29 Nymox Corp Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
DE60217507T2 (de) * 2001-07-19 2007-11-15 Nymox Corp., Saint-Laurent Peptide für die behandlung von tumoren und anderen zuständen, die das entfernen oder zerstören von zellen erfordern

Similar Documents

Publication Publication Date Title
JP2005506061A5 (cg-RX-API-DMAC7.html)
JP2005521383A5 (cg-RX-API-DMAC7.html)
JP2004534533A5 (cg-RX-API-DMAC7.html)
ES2342416T3 (es) Procedimiento de purificacion o produccion de una proteina mage.
JP2004529908A5 (cg-RX-API-DMAC7.html)
CN105705522B (zh) 针对低免疫原性蛋白的表位疫苗及其制法和用途
CN102596217B (zh) 经修饰的血管活性肠肽
JP2019196365A5 (cg-RX-API-DMAC7.html)
JP2021518745A5 (ja) アクチビンiib型受容体変異体および同変異体を含む医薬組成物
EA010435B1 (ru) Связывающиеся с tall-1 молекулы и их применение
JP2003531632A (ja) グルカゴンアンタゴニスト
JP2007523633A5 (cg-RX-API-DMAC7.html)
JP2021515572A5 (cg-RX-API-DMAC7.html)
JP2024513559A5 (cg-RX-API-DMAC7.html)
CN1202112A (zh) 增强胰腺功能的组合物
JP2004528266A (ja) 薬物送達用組成物
JP2003530088A5 (cg-RX-API-DMAC7.html)
CN111150841B (zh) 一种主动免疫调控微粒及其制备方法和应用
CA2378925A1 (en) Matrix-targeted fusion polypeptides for tissue regeneration and wound healing
RU2013113639A (ru) Иммунотерапевтический способ лечения рака простаты
CN118141903A (zh) 一种治疗犬黑色素瘤的环状rna疫苗
TW201302214A (zh) 治療或預防皮膚癌之類鋅手指胜肽、其表現質體、及包含其之醫藥組成物
CN100535005C (zh) 长链人胰岛素样生长因子(lr3igf-1)及其制备和应用方法
CN104379161A (zh) 促进血管生长的蛋白质及其用途
CN115605502A (zh) 用于预防或治疗纤维化疾病的重组融合蛋白